Search results

ciclosporin (Verkazia)

treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents (until the age of 18)

ciclosporin (Cequa)

Treatment of moderate-to-severe Dry Eye Disease (keratoconjunctivitis sicca) in adult patients who have not responded adequately to artificial tears.

ciclosporin (Vevizye)

Treatment of moderate to severe dry eye disease (keratoconjuctivitis sicca) in adult patients, which has not improved despite treatment with tear substitutes.

ciclosporin (Ikervis)

treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.

voclosporin (Lupkynis)

In combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN).

Mycophenolate sodium (Myfortic®)

In combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in adult patients receiving allogeneic renal transplants

apremilast (Otezla) plaque psoriasis

for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or pSoralen and ultraviolet A light (PUVA).

ustekinumab (Stelara)

For the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA).

tacrolimus, 5mg/ml concentrate for infusion and 0.5mg, 1mg, 5mg hard capsules (Prograf)

Prophylaxis of transplant rejection in heart allograft recipients

brodalumab (Kyntheum)

For the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy.

secukinumab (Cosentyx)

treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

infliximab (Remicade)

treatment of severely active ulcerative colitis in children and adolescents aged 6 to 17 years who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

infliximab 100mg powder for intravenous infusion (Remicade)

Severe plaque psoriasis

dimethyl fumarate (Skilarence)

Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.

tildrakizumab (Ilumetri)

Treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.